Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ:ZLAB), BeiGene Ltd (NASDAQ:BGNE), and Hutchmed China Ltd (NASDAQ:HCM), have been flagged by the SEC for failing to comply with a law governing US-listed companies.
In statements responding to the SEC's provisional list, all three companies suggest they expect more companies to come under regulatory scrutiny as they file their annual reports.
